Crucell, DSM Biologics N.V., Merus, PanGenetics deal

Merus received a license to the PER.C6 cell line from CRXL and CRXL's contract manufacturing partner, DSM. Merus will use the cell line to develop its Oligoclonics human antibody development technology. CRXL and DSM will receive an upfront payment and annual maintenance fees. ...